To hear about similar clinical trials, please enter your email below
Trial Title:
Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial
NCT ID:
NCT06333392
Condition:
Colorectal Neoplasia
Screening Colonoscopy
Colorectal Cancer
Colorectal Cancer Screening
Vasovagal Reaction
Conditions: Official terms:
Colorectal Neoplasms
Syncope, Vasovagal
Conditions: Keywords:
colorectal cancer screening
screening colonoscopy
underwater colonoscopy
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Prevention
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Total underwater colonoscopy
Description:
one grooup will be randomized to receive a total underwater colonoscopy
Arm group label:
Total underwater colonoscopy (TUC) group
Intervention type:
Procedure
Intervention name:
Conventional colonoscopy
Description:
one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal
Arm group label:
Conventional colonoscopy (CO2) group
Summary:
Colorectal cancer (CRC), the third most diagnosed cancer and second most common cause of
cancer death. CRCs develop from precursors like adenomas (about 70% of CRCs) or serrated
lesions (SSLs) (about 25-30% of CRCs). Colonoscopy is the cornerstone in CRC screening,
in screening programmes often as a work-up examination after a positive primary screening
test such as faecal immunochemical test (FIT). Norway and Sweden have recently launched a
nationwide faecal haemoglobin CRC screening programmes. Recently, both a Dutch and an
Austrian study showed that SSL detection rate (SSLDR) is inversely correlated to CRC at
follow-up. Consequently, improved SSLDR can reduce the risk of post-colonoscopy CRC. SSLs
are typically located in the right colon. They are flat, with indistinctive boarders, and
consequently easily missed or incompletely resected. A Norwegian study showed incomplete
resection of 40% of proximal SSLs. The prevalence of SSLs is higher in women than in men,
with women being on a threefold risk of developing CRC from SSLs. It seems like
post-colonoscopy CRC more often is caused by SSLs than by adenomas. Total underwater
colonoscopy (TUC) is a technique replacing conventional CO2 insufflation by water
infusion to distend the lumen and visualise the mucosa during withdrawal of the
colonoscope and simultaneously removal of water. There are several reasons to advocate
TUC:
1. SSLs will be more visible as they "float" on the submucosa and contract into the
lumen, while full distension by gas stretches the mucosa, making detection of flat
lesions more difficult.
2. Water works like a magnifying lens, making detection and detailed characterisation
of lesions easier.
3. uEMR is eased.
4. Improved bowel cleansing
The goal of this clinical trial is to compare colonoscopy outcomes for standard gas (CO2)
insufflation and TUC during withdrawal in patients participating in colonoscopy in the
Norwegian and Swedish colorectal cancer screening programme after a positive fecal
immunochemical test.
The overarching research questions of the present trial is whether colonoscopy outcomes
are improved when CO2 insufflation is replaced by TUC during withdrawal and whether the
new technique reduces the ecological footprint of the colonoscopy examination.
The project has five main hypotheses:
1. TUC is superior to the standard approach (CO2 withdrawal) regarding detection of
proximal SSLs.
2. TUC increases the rate of complete resection of lesions >= 10mm.
3. TUC reduces the rate of painful colonoscopies and vasovagal reactions.
4. TUC reduces the health care costs by reduced use of single use accessories and
reduced number of redundant colonoscopies to obtain polypfree colon.
5. TUC reduces the carbon footprint by reduced use of single use accessories.
If TUC is superior to gas insufflation, the technique may be implemented rapidly since
the technique is easy to learn. This study will increase endoscopy competence at
participating centres. The centres are involved in national colonoscopy training
programs, so the technique will quickly be passed on to other hospitals and screening
centres.
The trial can be linked to three of the Global Goals:
- Good health and well-being: The increased detection and improved complete removal of
sessile serrated lesions can subsequently decrease the risk of CRC and CRC mortality
during follow-up. TUC will probably reduce the rate of painful procedures and
vasovagal reactions and thus increase the acceptance of a screening programme.
Consequently, the project can contribute significantly to improve screening
effectiveness in Norway and Sweden, particularly in women (women have a higher risk
for SSLs and a higher risk of colorectal cancer developing from this type of
precursor).
- Gender equality: Women have a similar lifetime risk for CRC as men but less benefit
of screening regardless of whether they are screened by sigmoidoscopy, FIT or
colonoscopy. The reason is probably missed sessile serrated lesions in the proximal
colon. If TUC improves SSLDR and complete lesion resection, this may lead to an
equal benefit from CRC screening for women and men. Women have also a higher risk of
discomfort and pain during colonoscopy than men. It has been shown that women prefer
non-invasive screening modalities, potentially to avoid pain during colonoscopy,
even if colonoscopy may be the most beneficial screening method for women. If TUC
reduces the rate of painful colonoscopies, it can reduce women's barriers to attend
screening.
- Responsible consumption and production: The TUC technique will also reduce the
ecological footprint of colonoscopy activity due to reduced consumption of single
use accessories and reduced number of colonoscopies to achieve polyp free colon.
Furthermore, the cost for the health care system will be substantially reduced.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- All individuals referred to colonoscopy after a positive FIT screening at the
participating screening centres
Exclusion Criteria:
- Individuals with a CRC diagnosis within the last 10 years.
Gender:
All
Minimum age:
55 Years
Maximum age:
60 Years
Healthy volunteers:
No
Start date:
May 2024
Completion date:
December 2026
Lead sponsor:
Agency:
Vestre Viken Hospital Trust
Agency class:
Other
Collaborator:
Agency:
Ullevaal University Hospital
Agency class:
Other
Collaborator:
Agency:
Sahlgrenska University Hospital, Sweden
Agency class:
Other
Collaborator:
Agency:
Ostfold Hospital Trust
Agency class:
Other
Source:
Vestre Viken Hospital Trust
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06333392